The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...

Auvelity, already on the market for depression, avoids the black box warning carried by the only other approved treatment for ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...

A new study shows that changes linked to Alzheimer’s disease can speed up with age in people’s late 50s, long before memory ...

The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

Oral NMDA receptor antagonist gets an expanded indication ...

Should you receive a diagnosis of AD, many factors shape how symptoms unfold. The brain, even when under siege, retains an ...

The sub-study examined the impact of the therapy on prespecified Alzheimer’s plasma biomarkers in the subjects. Credit: ...

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...